Insider Transactions in Q2 2024 at Recursion Pharmaceuticals, Inc. (RXRX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2024
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
6,000
-1.11%
|
$42,000
$7.21 P/Share
|
|
Jun 27
2024
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+1.1%
|
$6,000
$1.06 P/Share
|
|
Jun 25
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$103,023
$9.51 P/Share
|
|
Jun 14
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.17%
|
$135,000
$9.27 P/Share
|
|
Jun 14
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+2.98%
|
$78,750
$2.22 P/Share
|
|
Jun 13
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.19%
|
$135,000
$9.32 P/Share
|
|
Jun 13
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+3.03%
|
$78,750
$2.22 P/Share
|
|
Jun 11
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$91,576
$8.45 P/Share
|
|
Jun 06
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,000
-6.59%
|
$450,000
$9.0 P/Share
|
|
Jun 05
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,000
-6.18%
|
$400,000
$8.42 P/Share
|
|
Jun 05
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
25,000
-3.0%
|
-
|
|
Jun 05
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
25,000
+2.91%
|
-
|
|
Jun 03
2024
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,097
+15.36%
|
-
|
|
Jun 03
2024
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,097
+11.36%
|
-
|
|
Jun 03
2024
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,097
+0.18%
|
-
|
|
Jun 03
2024
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,097
+20.21%
|
-
|
|
Jun 03
2024
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,097
+15.87%
|
-
|
|
May 30
2024
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
3,000
-0.56%
|
$24,000
$8.78 P/Share
|
|
May 30
2024
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+0.55%
|
$3,000
$1.06 P/Share
|
|
May 28
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$103,023
$9.17 P/Share
|
|
May 15
2024
|
Michael Secora Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,962
-0.97%
|
$119,620
$10.01 P/Share
|
|
May 15
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,082
-3.12%
|
$260,820
$10.01 P/Share
|
|
May 15
2024
|
David J Mauro Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-0.35%
|
$8,670
$10.01 P/Share
|
|
May 15
2024
|
Tina Marriott Larson President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,998
-1.84%
|
$99,980
$10.01 P/Share
|
|
May 14
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
20,054
-0.28%
|
$200,540
$10.12 P/Share
|
|
May 02
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,000
-2.91%
|
$400,000
$8.47 P/Share
|
|
May 02
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
21,296
+2.43%
|
-
|
|
May 01
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,000
-5.47%
|
$350,000
$7.73 P/Share
|
|
May 01
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
25,000
-2.66%
|
-
|
|
Apr 30
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$80,129
$7.95 P/Share
|
|
Apr 25
2024
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
3,000
-0.55%
|
$21,000
$7.67 P/Share
|
|
Apr 25
2024
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+0.55%
|
$3,000
$1.06 P/Share
|
|
Apr 17
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
23,124
-1.84%
|
$161,868
$7.58 P/Share
|
|
Apr 17
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+2.9%
|
$75,000
$2.22 P/Share
|
|
Apr 16
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.01%
|
$175,000
$7.67 P/Share
|
|
Apr 16
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+2.93%
|
$75,000
$2.22 P/Share
|
|
Apr 16
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$80,129
$7.66 P/Share
|
|
Apr 04
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
25,000
-100.0%
|
$225,000
$9.02 P/Share
|
|
Apr 04
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
25,000
+50.0%
|
-
|
|
Apr 04
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-4.09%
|
$360,000
$9.02 P/Share
|
|
Apr 03
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
25,000
-100.0%
|
$200,000
$8.84 P/Share
|
|
Apr 03
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
25,000
+50.0%
|
-
|
|
Apr 03
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-3.93%
|
$320,000
$8.84 P/Share
|
|
Apr 03
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
25,000
-2.4%
|
-
|
|
Apr 02
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$91,576
$8.82 P/Share
|
|
Apr 01
2024
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,467
+2.54%
|
-
|
|
Apr 01
2024
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,467
+1.62%
|
-
|
|
Apr 01
2024
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,001
+3.22%
|
-
|
|
Apr 01
2024
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,267
+2.1%
|
-
|